REVIEW PAPER
Advancement of SARS-CoV-2 infection in children
1
Department of Human Immunology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland
2
Student Circle of Immunology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland
3
Xi’an Medical University, Xi’an, Shanxi, China
4
Department of Pediatrics, Pediatric Endocrinology and Diabetes, University of Rzeszow, Rzeszow, Poland
5
Department of Pediatrics, Shanxi Provincial People’s Hospital, Xi’an, Shanxi, China
Submission date: 2021-01-12
Final revision date: 2021-03-11
Acceptance date: 2021-03-11
Publication date: 2021-07-01
Pediatr Pol 2021;96(2):129-133
KEYWORDS
TOPICS
ABSTRACT
Novel coronavirus disease 2019 (COVID-19) is a disease characterized by respiratory symptoms caused by novel coronavirus (SARS-CoV-2). Its pathogenesis is suggested to be related with ACE2 receptors, present in various organs. Children, as a special group of patients with COVID-19, have their own unique characteristics in terms of the disease’s course. The majority of children present with asymptomatic course or have mild symptoms. In severe cases COVID-19 may manifest as a multisystem inflammatory syndrome; thus, correct identification of children at risk is particularly important in the diagnostic process. The treatment options for this disease are still based on general therapy, and related drug therapy is still at the clinical trial stage.
REFERENCES (42)
1.
Diagnosis and Treatment of New Coronavirus Pneumonia (Trial Version 7). Chinese Medicine 2020; 15: 801-805.
2.
South AM, Brady TM, Flynn JT. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective. Hypertension 2020; 76: 16-22.
3.
Liu H, Gai S, Wang X, et al. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart. Cardiovasc Res 2020; 116: 1733-1741.
4.
Dehelean CA, Lazureanu V, Coricovac D, et al. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. J Clin Med 2020; 9: 2084.
5.
Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 2020; 369: 650-655.
6.
Castagnoli R, Votto M, Licari A, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr 2020; 174: 882-889.
7.
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367: 1260-1263.
8.
Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. Pediatrics 2020; 145: e20200702.
9.
Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv, 2020.
10.
Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet 2020; 395: e39.
11.
Xia J, Tong J, Liu M, et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection.
13.
Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv 2020; DOI: https://doi.org/10.1101/2020.0....
14.
Wang S, Guo L, Chen L, et al. A case report of neonatal 2019 coronavirus disease in China. Clin Infect Dis 2020; 71: 853-857.
15.
Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020, 395: 809-815.
16.
Jiehao C, Jin X, Daojiong L, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis 2020; 71: 1547-1551.
17.
Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020; 323: 1843-1844.
18.
Yaoling M, Shengying X, Min W, et al. Analysis of clinical features of 115 children infected with new coronavirus. Chinese Journal of Contemporary Pediatrics 2020; 22: 290-293.
19.
Mantovani A, Rinaldi E, Zusi C, et al. Coronavirus disease 2019 (COVID-19) in children and/or adolescents: a meta-analysis. Pediatr Res 2020; 89: 733-737. .
20.
Meena J, Yadav J, Saini L, et al. Clinical Features and Outcome of SARS-CoV-2 Infection in Children: A Systematic Review and Meta-analysis. Indian Pediatr 2020; 57: 820-826.
21.
Ye Q, Wang B, Zhang T, et al. The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19. Am J Physiol Gastrointest Liver Physiol 2020; 319: G245-G252.
22.
Xingfeng Ch, Furong Z, Ruihua X, et al. Cases of disseminated intravascular coagulation in 2 infants with novel coronavirus pneumonia. Chinese Journal of Integrated Chinese and Western Medicine 2020; 27: 46-49.
23.
Feng Ch, Zhisheng L, Furong Z, et al. China’s First New Critical Coronavirus Pneumonia in Children. Chinese Journal of Pediatrics 2020; 58: 179-182.
24.
Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395: 1607-1608.
25.
Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med 2020; 383: 347-358.
26.
Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020; 142: 429-436.
27.
Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020; 395: 1771-1778.
28.
Roe K. A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms. Inflammopharmacology 2020; 28:1219-1222.
29.
Ouldali N, Pouletty M, Mariani P, et al. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis. Lancet Child Adolesc Health 2020; 4: 662-668.
30.
Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ 2020; 369: m2094.
31.
MacDonald KL, Osterholm MT, Hedberg CW, et al. Toxic shock syndrome: a newly recognized complication of influenza and influenzalike illness. JAMA 1987; 257: 1053-1058.
32.
Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med 2020; 383: 334-346.
33.
Huang W, Berube J, McNamara M, et al. Lymphocyte Subset Counts in COVID-19 Patients: A Meta-Analysis. Cytometry A 2020; 97: 772-776.
34.
Zhen-Dong Y, Gao-Jun Z, Run-Ming J, et al. Clinical and transmission dynamics characteristics of 406 children with coronavirus disease 2019 in China: A review. J Infect 2020; 81: e11-e15.
35.
Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol 2020; 55: 1169-1174.
36.
Ma H, Hu J, Tian J, et al. A single-center, retrospective study of COVID-19 features in children: a descriptive investigation. BMC Med 2020; 18: 123.
37.
Liu H, Gai S, Wang X, et al. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart. Cardiovasc Res 2020; 116: 1733-1741.
38.
Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 9: 727-732.
39.
Remdesivir. COVID-19 Treatment Guidelines. Accessed December11, 2020.https://www.covid19treatmentgu....
40.
Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 2020; 34: 101615.
41.
Casirivimab. In: Drugs and Lactation Database (LactMed). National Library of Medicine (US); 2006. Accessed December 14, 2020. http://www.ncbi.nlm.nih.gov/bo....
42.
Statement on Casirivimab Plus Imdevimab EUA. COVID-19 Treatment Guidelines. Accessed December 14, 2020. https://www.covid19treatmentgu....
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
